about
Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress responseNew concepts of resistance in the treatment of Helicobacter pylori infectionsTranslating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosisRv2969c, essential for optimal growth inMycobacterium tuberculosis, is a DsbA-like enzyme that interacts with VKOR-derived peptides and has atypical features of DsbA-like disulfide oxidasesSlow elimination of multidrug-resistant tuberculosisCytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputumPhosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected miceHealth related quality of life among patients with tuberculosis and HIV in ThailandThe pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulationsThe Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancyReengineering redox sensitive GFP to measure mycothiol redox potential of Mycobacterium tuberculosis during infectionBactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection modelConfinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux MechanismA multi-scale approach to designing therapeutics for tuberculosisA computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatmentMetabolic Perspectives on PersistenceFacing resistance of H.pylori infectionSequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Enzymatic hydrolysis of trehalose dimycolate releases free mycolic acids during mycobacterial growth in biofilms.Mycobacterium tuberculosis PhoY Proteins Promote Persister Formation by Mediating Pst/SenX3-RegX3 Phosphate Sensing.Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment.Multimonth controlled small molecule release from biodegradable thin films.Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation modelBiosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.Profile of delamanid for the treatment of multidrug-resistant tuberculosisCharacterization and transcriptome analysis of Mycobacterium tuberculosis persisters.Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitorsImmunodiagnosis of tuberculosis: a dynamic view of biomarker discoveryIncreasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot studyAntigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesisAsymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibilityBacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors.Converting cancer therapies into cures: lessons from infectious diseasesThe roles of glutathione, glutathione peroxidase, glutathione reductase and the carbonyl protein in pulmonary and extra pulmonary tuberculosis.Nitric oxide, carbonyl protein, lipid peroxidation and correlation between antioxidant vitamins in different categories of pulmonary and extra pulmonary tuberculosisTuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
P2860
Q21263107-09646562-233E-4467-AA2D-C82CAB9F68C8Q24622513-051C1A47-B6F8-4151-8A69-8368790CBED1Q26824812-EE117B13-FA2A-4B46-BDDC-79F94BE6CE4CQ27680167-719FD3F7-B767-4372-A07D-979A9672CB82Q28278696-AAACC9E3-81C0-4DB9-A4A6-46F52501D132Q28472502-AF646B85-8856-4FEA-A1E3-8700236414B8Q28477281-A427F348-2936-4785-BBD2-8B55826CFC8BQ28478841-2531E2D1-5C8A-40B8-9E4F-53E812C3C659Q28485988-A36E33BC-80AA-493E-AC6B-C714A0996752Q28487516-F166903C-463A-4198-8313-B992690A1EA8Q28539327-F17A2810-F035-4C42-8F9E-ABF065E59311Q28539383-3E856314-FE58-4BC2-9D7D-C34D1781895DQ28547410-76673FBC-0276-4784-896E-0E28D867771BQ28647309-ACFF48D0-6BA5-49C8-8E3A-9C11AA384CB3Q28649754-0282BE6D-7211-410B-A9BE-08183D37F98BQ30398195-6BF7A0A4-D67D-493F-AA91-960060171AD7Q33596218-F5252CA3-6B45-4880-8719-A22C51CB75F8Q33727000-1A8128D5-031B-47F8-BC31-AC6279C2B18BQ33885084-0B97CE6C-FB13-4809-B4B4-6199A007337BQ33911275-1DA4C549-6446-43B0-9384-091F92347009Q33947806-A13D36F0-CD84-44EE-93A3-1FEA43A480FAQ34065647-5887E481-3D19-49BC-A091-E27FFEF7B11DQ34082780-8F5B75F1-087E-4F5A-99B6-7DED2D6972E4Q34881104-DB98AF52-E515-4FC7-84C4-E10DD1CCB5F9Q34976154-8A42EC0E-1C34-482E-8813-C473CBC128C0Q35051649-9EB49D89-6845-4CD7-88EC-29D58BE6CD7BQ35057495-85317E21-E284-4C1D-A65A-3D7EE7215D26Q35058352-19CC2E7C-AA00-47A0-8CD0-A6FF3B230BF2Q35243846-5A3E8100-1C54-4950-ACAC-CF3CA1141990Q35361654-5ED0D209-8068-4421-A5E5-A856B0B28025Q35539764-05D45389-338C-4295-A84D-D47CE80D92C1Q35867371-A04A868E-8F4A-4318-881E-E49CA03E468DQ36096651-40DC54C0-0C52-4115-9EF5-E077FF1D6423Q36100081-95CDB504-8405-4021-9BAD-A83B523C5931Q36105224-91EF6235-BABC-4725-8303-A4C35EB33925Q36301709-2EA6FD82-EA7D-472E-9E8B-0C56EDA67B6DQ36481357-40126171-1DE9-4B16-8B75-062BC0CB3CBFQ36776963-D7A2EFFC-91AF-4174-B755-78316FB3DD90Q36942918-EA82F36B-31AE-4B23-A24B-FB6E752BDAF3Q37014319-CDFCFDA8-9778-4EC2-B534-021153A7A315
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Why is long-term therapy required to cure tuberculosis?
@ast
Why is long-term therapy required to cure tuberculosis?
@en
type
label
Why is long-term therapy required to cure tuberculosis?
@ast
Why is long-term therapy required to cure tuberculosis?
@en
prefLabel
Why is long-term therapy required to cure tuberculosis?
@ast
Why is long-term therapy required to cure tuberculosis?
@en
P2860
P1433
P1476
Why is long-term therapy required to cure tuberculosis?
@en
P2093
Lynn E Connolly
P2860
P356
10.1371/JOURNAL.PMED.0040120
P407
P577
2007-03-01T00:00:00Z